Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$12.58
+0.6%
$12.68
$3.69
$13.29
$718.13M0.011.01 million shs3.20 million shs
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$19.38
+4.0%
$19.74
$12.58
$23.77
$3.08B0.991.76 million shs2.31 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$24.17
+3.2%
$23.36
$7.91
$28.72
$3.04B0.871.20 million shs1.11 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
0.00%0.00%0.00%0.00%+220.92%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
0.00%+1.30%-6.19%-13.02%+38.90%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.00%+0.21%-7.56%+16.22%+159.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$12.58
+0.6%
$12.68
$3.69
$13.29
$718.13M0.011.01 million shs3.20 million shs
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$19.38
+4.0%
$19.74
$12.58
$23.77
$3.08B0.991.76 million shs2.31 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$24.17
+3.2%
$23.36
$7.91
$28.72
$3.04B0.871.20 million shs1.11 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
0.00%0.00%0.00%0.00%+220.92%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
0.00%+1.30%-6.19%-13.02%+38.90%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.00%+0.21%-7.56%+16.22%+159.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
2.10
Hold$24.5094.75% Upside
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
2.87
Moderate Buy$34.2576.73% Upside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.55
Moderate Buy$33.8940.21% Upside

Current Analyst Ratings Breakdown

Latest ATXS, DNLI, RCUS, and MOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Lower Price TargetOverweight$40.00 ➝ $35.00
5/22/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Set Price Target$31.00
5/18/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Initiated CoverageBuy$30.00 ➝ $35.00
5/14/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Lower Price TargetOverweight$42.00 ➝ $40.00
5/11/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Boost Price TargetEqual Weight$20.00 ➝ $22.00
5/11/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Reiterated RatingBuy$39.00
5/8/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Lower Price TargetOutperform$25.00 ➝ $23.00
5/7/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Boost Price TargetBuy$30.00 ➝ $34.00
5/4/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
UpgradeStrong-Buy
4/22/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Lower Price TargetOutperform$40.00 ➝ $35.00
4/20/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Reiterated RatingSell (D-)
(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$706K1,017.18N/AN/A$3.97 per share3.17
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M9.31N/AN/A$5.84 per share3.32
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$247M12.31N/AN/A$4.17 per share5.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$94.26M-$2.14N/AN/AN/AN/A-68.81%-41.12%N/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)

Latest ATXS, DNLI, RCUS, and MOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A
5/5/2026Q1 2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million
2/26/2026Q4 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.75-$0.73+$0.02-$0.73$2.86 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/AN/A
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/A
10.78
10.78
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
0.01
9.28
9.28
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.19
4.04
4.04

Institutional Ownership

CompanyInstitutional Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
98.98%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%

Insider Ownership

CompanyInsider Ownership
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
4.50%
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12.50%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3057.09 million54.52 millionOptionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
430158.71 million138.87 millionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500125.77 million113.70 millionOptionable

Recent News About These Companies

Arcus (RCUS) Q1 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astria Therapeutics stock logo

Astria Therapeutics NASDAQ:ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$19.38 +0.74 (+3.97%)
As of 04:00 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 05/22/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$24.17 +0.74 (+3.16%)
As of 03:58 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.